Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1001837 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31049529 | 0.92 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL1746631 | 0.92 | KMT2A (0.44) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL30945369 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL30945375 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL30945377 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL2182540 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL18614183 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL2182772 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 | |
| SCHEMBL4747100 | 0.90 | KMT2A (0.45) | KMT2AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023122945-A1 | CYCLIC POLYPEPTIDE COMPOUNDS AND USES THEREOF | 知和(山东)大药厂有限公司 | 2023-07-06 | — | — | WO | disclosed |
| CN-114057839-A | Cyclic polypeptide compound and use thereof | 石家庄创肽生物医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-2426139-B1 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD (IL) | 2014-10-01 | — | — | EP | disclosed |
| US-8410059-B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2013-04-02 | — | — | US | disclosed |
| EP-1541585-B1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD (IL) | 2013-01-30 | — | — | EP | disclosed |
| EP-2426139-A1 | CXCR4 antagonist and use thereof | Biokine Therapeutics Ltd. (IL) | 2012-03-07 | — | — | EP | disclosed |
| US-20110269686-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2011-11-03 | — | — | US | disclosed |
| US-8017585-B2 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2011-09-13 | — | — | US | disclosed |
| US-7868135-B2 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | BIOWEST THERAPEUTICS INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| EP-2147925-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2010-01-27 | — | — | EP | disclosed |
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | BIOKINE THERAPEUTICS LTD. (IL) | 2009-07-16 | — | — | US | disclosed |
| US-7423007-B2 | Cxcr4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD. (IL) | 2008-09-09 | — | — | US | disclosed |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-23 | — | — | US | disclosed |
| EP-1656390-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | MIGENIX INC. (CA) | 2005-07-14 | — | — | US | disclosed |
| EP-1541585-A1 | CXCR4 ANTAGONIST AND USE THEREOF | Fujii, Nobutaka (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005000878-A2 | COMPOSITIONS OF LIPOPEPTIDE ANTIBIOTIC DERIVATIVES AND METHODS OF USE THEREOF | MIGENIX INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181897-A1 | CXCR4 ANTAGONIST AND USE THEREOF | CXCR4, ACKR3, CXCR1 | KMT2A 1987/4885FABP5 1741/4885FABP7 3192/4885 |
| US-20050153876-A1 | Compositions of lipopeptide antibiotic derivatives and methods of use thereof | NRDC, NOD2, NGLY1 | KMT2A 4429/4885FABP5 1318/4885FABP7 2995/4885 |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | CXCR4, ACKR3, CXCR1 | KMT2A 1987/4885FABP5 1741/4885FABP7 3192/4885 |
| US-20110269686-A1 | CXCR4 ANTAGONIST AND USE THEREOF | CXCR4, ACKR3, CXCR1 | KMT2A 1987/4885FABP5 1741/4885FABP7 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.